


Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/301,380
Filing Date	June 15, 2001
First Named Inventor	Murphy, Gerald P.
Group Art Unit	1635
Examiner Name	M. Schmidt
Attorney Docket Number	20093A-002100US

Total Number of Pages in This Submission

1

RECEIVED
FEB 03 2003
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☒ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☒ Extension of Time Request

☐ Express Abandonment Request

☐ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☒ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s)

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

Formal Drawings (Figs. 1 - 26B); Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name

Townsend and Townsend and Crew LLP

Brian W. Poor

Reg. No. 32,928

Signature

Brian W. Poor

Date

January 28, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

January 28, 2003

Typed or printed name

Jennifer M. Smolen

Signature

J. Smolen

Date

January 28, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SE 5015396 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

January 28, 2003

[Signature]



#22/K.T.
2/5
[Signature]

PATENT

Attorney Docket No.: 20093A-002100US

w/DRUGS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERALD P. MURPHY *et al.*

Application No.: 09/301,380

Filed: June 15, 2001

For: NR-CAM GENE, NUCLEIC ACIDS
AND NUCLEIC ACID PRODUCTS
FOR THERAPEUTIC AND
DIAGNOSTIC USES FOR
TUMORS

Examiner: M. Schmidt

Art Unit: 1635

RECEIVED

FEB 03 2003

TECH CENTER 1600/2900

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action having a mailing date of August 28, 2002, please amend the application as follows:

IN THE SPECIFICATION:

Kindly replace the following paragraphs with the substitute paragraphs as indicated. An Appendix showing all changes to the claims is attached to this amendment as required by 37 CFR § 1.121(b).

Please replace the paragraph beginning at page 3, line 5, with the following substitute paragraph:

Glioblastoma multiforme are high grade astrocytomas that grow very rapidly and contain cells that are very malignant (Thapar and Laws, 1993, CA Cancer J. Clin., 43:263-271).

B¹